PortalPublikationenInvestigational treatment options in microscopic colitis

Investigational treatment options in microscopic colitis

Standard

Investigational treatment options in microscopic colitis. / Madisch, Ahmed; Morgner, Andrea; Stolte, Manfred; Miehlke, Stephan.

in: EXPERT OPIN INV DRUG, Jahrgang 17, Nr. 12, 12.2008, S. 1829-37.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Madisch, A, Morgner, A, Stolte, M & Miehlke, S 2008, 'Investigational treatment options in microscopic colitis', EXPERT OPIN INV DRUG, Jg. 17, Nr. 12, S. 1829-37. https://doi.org/10.1517/13543780802514500

APA

Madisch, A., Morgner, A., Stolte, M., & Miehlke, S. (2008). Investigational treatment options in microscopic colitis. EXPERT OPIN INV DRUG, 17(12), 1829-37. https://doi.org/10.1517/13543780802514500

Vancouver

Madisch A, Morgner A, Stolte M, Miehlke S. Investigational treatment options in microscopic colitis. EXPERT OPIN INV DRUG. 2008 Dez;17(12):1829-37. https://doi.org/10.1517/13543780802514500

Bibtex

@article{cd48e160a302452fb46897b6521a4a04,
title = "Investigational treatment options in microscopic colitis",
abstract = "Collagenous and lymphocytic colitis are the two recognized major presentations of microscopic colitis. Both diseases present with chronic watery diarrhea and a chronic inflammatory infiltrate in the colonic mucosa without specific endoscopic abnormalities, and hence diagnosis is established by histology. Recent epidemiological studies suggest that microscopic colitis may affect as many patients as Crohn's disease or ulcerative colitis. The cause of these diseases is unknown; however, several lines of evidence support the hypothesis of mucosal injury from an unknown agent in the fecal stream. Due to the lack of disease causality, therapeutic management of microscopic colitis is now directed primarily at symptoms' resolution or improvement. Based on current evidence, oral budesonide represents an effective treatment option for patients with microscopic colitis to achieve and maintain remission. Other anti-inflammatory drugs such as mesalazine or bismuth subsalicylate are now under evaluation. The optimal long-term management strategy of microscopic colitis, however, remains an unsolved issue.",
keywords = "Adrenal Cortex Hormones, Animals, Colitis, Humans, Probiotics, Quality of Life, Randomized Controlled Trials as Topic, Journal Article, Review",
author = "Ahmed Madisch and Andrea Morgner and Manfred Stolte and Stephan Miehlke",
year = "2008",
month = dec,
doi = "10.1517/13543780802514500",
language = "English",
volume = "17",
pages = "1829--37",
journal = "EXPERT OPIN INV DRUG",
issn = "1354-3784",
publisher = "informa healthcare",
number = "12",

}

RIS

TY - JOUR

T1 - Investigational treatment options in microscopic colitis

AU - Madisch, Ahmed

AU - Morgner, Andrea

AU - Stolte, Manfred

AU - Miehlke, Stephan

PY - 2008/12

Y1 - 2008/12

N2 - Collagenous and lymphocytic colitis are the two recognized major presentations of microscopic colitis. Both diseases present with chronic watery diarrhea and a chronic inflammatory infiltrate in the colonic mucosa without specific endoscopic abnormalities, and hence diagnosis is established by histology. Recent epidemiological studies suggest that microscopic colitis may affect as many patients as Crohn's disease or ulcerative colitis. The cause of these diseases is unknown; however, several lines of evidence support the hypothesis of mucosal injury from an unknown agent in the fecal stream. Due to the lack of disease causality, therapeutic management of microscopic colitis is now directed primarily at symptoms' resolution or improvement. Based on current evidence, oral budesonide represents an effective treatment option for patients with microscopic colitis to achieve and maintain remission. Other anti-inflammatory drugs such as mesalazine or bismuth subsalicylate are now under evaluation. The optimal long-term management strategy of microscopic colitis, however, remains an unsolved issue.

AB - Collagenous and lymphocytic colitis are the two recognized major presentations of microscopic colitis. Both diseases present with chronic watery diarrhea and a chronic inflammatory infiltrate in the colonic mucosa without specific endoscopic abnormalities, and hence diagnosis is established by histology. Recent epidemiological studies suggest that microscopic colitis may affect as many patients as Crohn's disease or ulcerative colitis. The cause of these diseases is unknown; however, several lines of evidence support the hypothesis of mucosal injury from an unknown agent in the fecal stream. Due to the lack of disease causality, therapeutic management of microscopic colitis is now directed primarily at symptoms' resolution or improvement. Based on current evidence, oral budesonide represents an effective treatment option for patients with microscopic colitis to achieve and maintain remission. Other anti-inflammatory drugs such as mesalazine or bismuth subsalicylate are now under evaluation. The optimal long-term management strategy of microscopic colitis, however, remains an unsolved issue.

KW - Adrenal Cortex Hormones

KW - Animals

KW - Colitis

KW - Humans

KW - Probiotics

KW - Quality of Life

KW - Randomized Controlled Trials as Topic

KW - Journal Article

KW - Review

U2 - 10.1517/13543780802514500

DO - 10.1517/13543780802514500

M3 - SCORING: Journal article

C2 - 19012499

VL - 17

SP - 1829

EP - 1837

JO - EXPERT OPIN INV DRUG

JF - EXPERT OPIN INV DRUG

SN - 1354-3784

IS - 12

ER -